PubMed:19136585 / 0-421 JSONTXT

{"project":"Glycan-Motif","denotations":[{"id":"T1","span":{"begin":134,"end":151},"obj":"https://glytoucan.org/Structures/Glycans/G20420WT"},{"id":"T2","span":{"begin":134,"end":151},"obj":"https://glytoucan.org/Structures/Glycans/G74621DY"},{"id":"T3","span":{"begin":134,"end":151},"obj":"https://glytoucan.org/Structures/Glycans/G84224TW"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T1","span":{"begin":134,"end":151},"obj":"Glycan_Motif"}],"attributes":[{"id":"A1","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G84224TW"},{"id":"A2","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G74621DY"},{"id":"A3","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G20420WT"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":134,"end":151},"obj":"https://glytoucan.org/Structures/Glycans/G20420WT"},{"id":"T2","span":{"begin":134,"end":151},"obj":"https://glytoucan.org/Structures/Glycans/G74621DY"},{"id":"T3","span":{"begin":134,"end":151},"obj":"https://glytoucan.org/Structures/Glycans/G84224TW"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"Glycosmos6-MAT","denotations":[{"id":"T1","span":{"begin":170,"end":177},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":199},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":199},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":199},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"Glycosmos6-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":134,"end":151},"obj":"http://www.glycoepitope.jp/epitopes/EP0078"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":23,"end":53},"obj":"gene:10317"},{"id":"T1","span":{"begin":170,"end":187},"obj":"disease:C0699790"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T1","span":{"begin":134,"end":151},"obj":"FMAID:82821"},{"id":"_T2","span":{"begin":134,"end":151},"obj":"FMAID:196817"},{"id":"_T3","span":{"begin":170,"end":177},"obj":"FMAID:104231"},{"id":"_T4","span":{"begin":170,"end":177},"obj":"FMAID:14543"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":23,"end":51},"obj":"http://www.uniprot.org/uniprot/O75752"},{"id":"T2","span":{"begin":238,"end":266},"obj":"http://www.uniprot.org/uniprot/O75752"},{"id":"T3","span":{"begin":23,"end":51},"obj":"http://www.uniprot.org/uniprot/O60512"},{"id":"T4","span":{"begin":238,"end":266},"obj":"http://www.uniprot.org/uniprot/O60512"},{"id":"T5","span":{"begin":396,"end":402},"obj":"http://www.uniprot.org/uniprot/Q92988"},{"id":"T6","span":{"begin":411,"end":417},"obj":"http://www.uniprot.org/uniprot/Q92988"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":30,"end":51},"obj":"http://www.uniprot.org/uniprot/P23336"},{"id":"T2","span":{"begin":245,"end":266},"obj":"http://www.uniprot.org/uniprot/P23336"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":23,"end":27},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T2","span":{"begin":23,"end":27},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T3","span":{"begin":178,"end":187},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/166034"},{"id":"T4","span":{"begin":238,"end":242},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T5","span":{"begin":238,"end":242},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T6","span":{"begin":268,"end":272},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T7","span":{"begin":268,"end":272},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T8","span":{"begin":304,"end":308},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T9","span":{"begin":304,"end":308},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T10","span":{"begin":396,"end":400},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"},{"id":"T11","span":{"begin":396,"end":400},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T12","span":{"begin":411,"end":415},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T13","span":{"begin":411,"end":415},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":95,"end":104},"obj":"http://purl.obolibrary.org/obo/GO_0009058"},{"id":"T2","span":{"begin":347,"end":359},"obj":"http://purl.obolibrary.org/obo/GO_0009058"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":188,"end":192},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"UBERON-AE","denotations":[{"id":"T1","span":{"begin":170,"end":177},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"19136585-0#23#53#gene10317","span":{"begin":23,"end":53},"obj":"gene10317"},{"id":"19136585-0#170#187#diseaseC0699790","span":{"begin":170,"end":187},"obj":"diseaseC0699790"}],"relations":[{"id":"23#53#gene10317170#187#diseaseC0699790","pred":"associated_with","subj":"19136585-0#23#53#gene10317","obj":"19136585-0#170#187#diseaseC0699790"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlycoBiology-MAT","denotations":[{"id":"T1","span":{"begin":170,"end":177},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlycoBiology-Epitope","denotations":[{"id":"PD-GlycoEpitope-B_T1","span":{"begin":134,"end":151},"obj":"http://www.glycoepitope.jp/epitopes/EP0078"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G93924TT\""},{"id":"GlycanIUPAC_T4","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G25565DN\""},{"id":"GlycanIUPAC_T7","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G97215EV\""},{"id":"GlycanIUPAC_T10","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G79664KO\""},{"id":"GlycanIUPAC_T13","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G24107FU\""},{"id":"GlycanIUPAC_T16","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G09864UE\""},{"id":"GlycanIUPAC_T19","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G28032MC\""},{"id":"GlycanIUPAC_T22","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G28005UP\""},{"id":"GlycanIUPAC_T25","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G92708AT\""},{"id":"GlycanIUPAC_T28","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G73757UC\""},{"id":"GlycanIUPAC_T31","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G51062DM\""},{"id":"GlycanIUPAC_T34","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G05866BJ\""},{"id":"GlycanIUPAC_T37","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G87394FZ\""},{"id":"GlycanIUPAC_T40","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G03871NF\""},{"id":"GlycanIUPAC_T43","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G29377VE\""},{"id":"GlycanIUPAC_T46","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G33457CX\""},{"id":"GlycanIUPAC_T49","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G97368GU\""},{"id":"GlycanIUPAC_T52","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G18512EL\""},{"id":"GlycanIUPAC_T55","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G41137VS\""},{"id":"GlycanIUPAC_T58","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G30521NA\""},{"id":"GlycanIUPAC_T61","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G19388CD\""},{"id":"GlycanIUPAC_T64","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G53151FU\""},{"id":"GlycanIUPAC_T67","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G27105XC\""},{"id":"GlycanIUPAC_T70","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G91210VM\""},{"id":"GlycanIUPAC_T73","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G40841DE\""},{"id":"GlycanIUPAC_T76","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G71241HP\""},{"id":"GlycanIUPAC_T79","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G84636BJ\""},{"id":"GlycanIUPAC_T82","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G47905LJ\""},{"id":"GlycanIUPAC_T85","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G39340DV\""},{"id":"GlycanIUPAC_T88","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G48801AQ\""},{"id":"GlycanIUPAC_T91","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G14573NX\""},{"id":"GlycanIUPAC_T94","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G56762TR\""},{"id":"GlycanIUPAC_T97","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G20013XO\""},{"id":"GlycanIUPAC_T100","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G39504DR\""},{"id":"GlycanIUPAC_T103","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G35218RQ\""},{"id":"GlycanIUPAC_T106","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G53048SH\""},{"id":"GlycanIUPAC_T109","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G78418IX\""},{"id":"GlycanIUPAC_T112","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G09780OD\""},{"id":"GlycanIUPAC_T115","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G56359GL\""},{"id":"GlycanIUPAC_T118","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G78941YC\""},{"id":"GlycanIUPAC_T121","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G26829FC\""},{"id":"GlycanIUPAC_T124","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G88538ZC\""},{"id":"GlycanIUPAC_T127","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G46593ZR\""},{"id":"GlycanIUPAC_T130","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G43523TH\""},{"id":"GlycanIUPAC_T133","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G36445ON\""},{"id":"GlycanIUPAC_T136","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G67363FK\""},{"id":"GlycanIUPAC_T139","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G17562KT\""},{"id":"GlycanIUPAC_T142","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G24774YJ\""},{"id":"GlycanIUPAC_T145","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G32162UO\""},{"id":"GlycanIUPAC_T148","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G89163RR\""},{"id":"GlycanIUPAC_T151","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G99522DY\""},{"id":"GlycanIUPAC_T154","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G59246IF\""},{"id":"GlycanIUPAC_T157","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G95321NT\""},{"id":"GlycanIUPAC_T160","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G17531ZI\""},{"id":"GlycanIUPAC_T163","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G54322SU\""},{"id":"GlycanIUPAC_T166","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G72010DO\""},{"id":"GlycanIUPAC_T169","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G44269EP\""},{"id":"GlycanIUPAC_T172","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G57335AD\""},{"id":"GlycanIUPAC_T175","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G60837LL\""},{"id":"GlycanIUPAC_T178","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G61929XX\""},{"id":"GlycanIUPAC_T181","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G88747RA\""},{"id":"GlycanIUPAC_T184","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G47955HA\""},{"id":"GlycanIUPAC_T187","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G60982WS\""},{"id":"GlycanIUPAC_T190","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G37035KG\""},{"id":"GlycanIUPAC_T193","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G46297FI\""},{"id":"GlycanIUPAC_T196","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G35475KI\""},{"id":"GlycanIUPAC_T199","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G29771JN\""},{"id":"GlycanIUPAC_T202","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G61285YR\""},{"id":"GlycanIUPAC_T205","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G54785MW\""},{"id":"GlycanIUPAC_T208","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G53039GT\""},{"id":"GlycanIUPAC_T211","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G00601HK\""},{"id":"GlycanIUPAC_T214","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G10485IJ\""},{"id":"GlycanIUPAC_T217","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G16393IB\""},{"id":"GlycanIUPAC_T220","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G98436FZ\""},{"id":"GlycanIUPAC_T223","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G18825IA\""},{"id":"GlycanIUPAC_T226","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G61281HQ\""},{"id":"GlycanIUPAC_T229","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G07798TI\""},{"id":"GlycanIUPAC_T232","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G55921QA\""},{"id":"GlycanIUPAC_T235","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G99066DL\""},{"id":"GlycanIUPAC_T238","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G33451PQ\""},{"id":"GlycanIUPAC_T241","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G02111XU\""},{"id":"GlycanIUPAC_T244","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G85193OM\""},{"id":"GlycanIUPAC_T247","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G89174YQ\""},{"id":"GlycanIUPAC_T250","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G28802LE\""},{"id":"GlycanIUPAC_T253","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G56061JK\""},{"id":"GlycanIUPAC_T256","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G68941BC\""},{"id":"GlycanIUPAC_T259","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G55436FC\""},{"id":"GlycanIUPAC_T262","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G24002PU\""},{"id":"GlycanIUPAC_T265","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G61387SV\""},{"id":"GlycanIUPAC_T268","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G31834HW\""},{"id":"GlycanIUPAC_T271","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G35324RT\""},{"id":"GlycanIUPAC_T274","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G34803QO\""},{"id":"GlycanIUPAC_T277","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G92898FF\""},{"id":"GlycanIUPAC_T280","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G01318VX\""},{"id":"GlycanIUPAC_T283","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G83200MX\""},{"id":"GlycanIUPAC_T286","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G56286UC\""},{"id":"GlycanIUPAC_T289","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G07304QA\""},{"id":"GlycanIUPAC_T292","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G06868OU\""},{"id":"GlycanIUPAC_T295","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G12647BS\""},{"id":"GlycanIUPAC_T298","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G51841DF\""},{"id":"GlycanIUPAC_T301","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G32122AJ\""},{"id":"GlycanIUPAC_T304","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G41125MN\""},{"id":"GlycanIUPAC_T307","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G16093XS\""},{"id":"GlycanIUPAC_T310","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G62425IX\""},{"id":"GlycanIUPAC_T313","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G15673TO\""},{"id":"GlycanIUPAC_T316","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G32857IK\""},{"id":"GlycanIUPAC_T319","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G60047CJ\""},{"id":"GlycanIUPAC_T322","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G55718ZB\""},{"id":"GlycanIUPAC_T325","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G88355ZE\""},{"id":"GlycanIUPAC_T328","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G11283PA\""},{"id":"GlycanIUPAC_T331","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G71737IZ\""},{"id":"GlycanIUPAC_T334","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G60912WZ\""},{"id":"GlycanIUPAC_T337","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G99655SO\""},{"id":"GlycanIUPAC_T340","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G10300TW\""},{"id":"GlycanIUPAC_T343","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G89509FL\""},{"id":"GlycanIUPAC_T346","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G31465TH\""},{"id":"GlycanIUPAC_T349","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G94101LU\""},{"id":"GlycanIUPAC_T352","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G38610BB\""},{"id":"GlycanIUPAC_T355","span":{"begin":392,"end":395},"obj":"\"http://rdf.glycoinfo.org/glycan/G85893UF\""}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":170,"end":177},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":170,"end":187},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0002032"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlyCosmos15-HP","denotations":[{"id":"T1","span":{"begin":178,"end":187},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0030731"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T1","span":{"begin":170,"end":187},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0002032"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlyCosmos15-NCBITAXON","denotations":[{"id":"T1","span":{"begin":164,"end":169},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlyCosmos15-MAT","denotations":[{"id":"T1","span":{"begin":170,"end":177},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":199},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":199},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":199},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T1","span":{"begin":0,"end":199},"obj":"Sentence"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlyCosmos15-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":134,"end":151},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A1","pred":"glycoepitope_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0078"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":164,"end":169},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"GlyCosmos-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":134,"end":151},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A1","pred":"glycoepitope_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0078"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"Anatomy-MAT","denotations":[{"id":"T1","span":{"begin":170,"end":177},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}

{"project":"HP-phenotype","denotations":[{"id":"T1","span":{"begin":178,"end":187},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0030731"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Enhanced expression of beta 3-galactosyltransferase 5 activity is sufficient to induce in vivo synthesis of extended type 1 chains on lactosylceramides of selected human colonic carcinoma cell lines.\nIn general, an elevated expression of beta 3-galactosyltransferase (beta 3GalT) activity contributed by beta 3GalT5 correlates well with increased biosynthesis and expression of type 1 chain (Gal beta 1-3GlcNAc beta 1-) d"}